Clinical Trials Sponsored by Sanofi-Regeneron

Total 3763 results

Sanofi
Regeneron Pharmaceuticals

Not yet recruiting

Study in Paediatric Patients With Atopic Dermatitis Treated With Dupilumab in Spain (PROADAP)

Atopic Dermatitis
Sanofi
Regeneron Pharmaceuticals

Recruiting

A Proof-of-Concept Study to Assess the Efficacy, Safety and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Non-cystic Fibrosis Bronchiectasis

Bronchiectasis

United Kingdom, Japan, United States, Israel, Canada
Sanofi
Regeneron Pharmaceuticals

Recruiting

A Study to Investigate Long-term Safety and Tolerability of Itepekimab in Participants With COPD (AERIFY-4)

Chronic Obstructive Pulmonary Disease

United States, China, Hungary, Israel, Poland, Taiwan, Canada, Chile, Korea, Republic of, Japan
Regeneron Pharmaceuticals
Sanofi

Recruiting

Neoadjuvant Cemiplimab for the Treatment of Resectable NSCLC, HCC, and HNSCC in Adult Patients

Hepatocellular Carcinoma | Non-small Cell Lung Cancer | Head and Neck Squamous Cell Carcinoma

United States
Regeneron Pharmaceuticals
Sanofi

Recruiting

Intralesional Cemiplimab for Adult Patients With Cutaneous Squamous Cell Carcinoma or Basal Cell Carcinoma

Basal Cell Carcinoma | Cutaneous Squamous Cell Carcinoma

United States
Sanofi
Regeneron Pharmaceuticals

Recruiting

A Repeated Dose-finding Study of Sarilumab in Children and Adolescents With Systemic Juvenile Idiopathic Arthritis (SKYPS)

Juvenile Idiopathic Arthritis

Argentina, Bulgaria, Canada, Finland, France, Germany, Ireland, Italy, Russian Federation, Spain, United Kingdom
Sanofi
Regeneron Pharmaceuticals

Completed

Dupilumab in Japanese Patients With Atopic Dermatitis

Atopic Dermatitis

Japan
Sanofi
Regeneron Pharmaceuticals

Active, not recruiting

Pivotal Study to Assess the Efficacy, Safety and Tolerability of Dupilumab in Patients With Moderate to Severe COPD With Type 2 Inflammation (NOTUS)

Chronic Obstructive Pulmonary Disease

Greece, Belgium, Spain, Argentina, Hungary, South Africa, United Kingdom, France, Latvia, Germany, Netherlands, Russian Federation, Ukraine, United States, Australia, Brazil, Bulgaria, Canada, Chile, Colombia, Czechia, Lithuania, Me... and more
Sanofi
Regeneron Pharmaceuticals

Active, not recruiting

Observational Study of Patients Receiving Dupixent® for Atopic Dermatitis (AD) (GLOBOSTAD)

Dermatitis Atopic

Spain, Czechia, Italy, Israel, Argentina, Australia, Austria, Belgium, Colombia, Finland, France, Greece, Japan, Kuwait, Mexico, Netherlands, Norway, Portugal, Russian Federation, Saudi Arabia, Taiwan, United Arab Emirates
Sanofi
Regeneron Pharmaceuticals

Completed

Dupilumab in CRSsNP (Liberty CRSsNP)

Chronic Sinusitis | Sinusitis | Chronic Rhinosinusitis Without Nasal Polyps | Sinus Disorder | Respiratory Disorder

Belgium, Spain, Argentina, Ukraine, Portugal, China, United States, Canada, Chile, Hungary, Korea, Republic of, Russian Federation, Sweden
Sanofi
Regeneron Pharmaceuticals

Completed

A Phase 4, Randomized, Double-blind, Placebo-controlled,Multicenter, Parallel-group Study of the Effect of Dupilumab on Sleep Disturbance in Patients With Uncontrolled Persistent Asthma (MORPHEO)

Asthma

Spain, United States, Argentina, Canada, Germany, Italy, Netherlands, Portugal, Russian Federation, Ukraine, United Kingdom
Regeneron Pharmaceuticals
Sanofi

Active, not recruiting

Study of Patients Receiving DUPIXENT® for Atopic Dermatitis (AD) (PROSE)

Dermatitis, Atopic

United States, Canada
Sanofi
Regeneron Pharmaceuticals

Completed

A Study to Investigate the Pharmacokinetics (PK), Tolerability and Safety of Two Different Dupilumab Drug Products in Healthy Participants.

Healthy Volunteers

United States
Sanofi
Regeneron Pharmaceuticals

Completed

A Study to Investigate the Pharmacokinetics, Tolerability and Safety of Two Different Dupilumab Drug Products in Healthy Participants

Healthy Volunteer

United States
Sanofi
Regeneron Pharmaceuticals

Active, not recruiting

The Effect of Dupilumab on Lung Inflammation and Related Changes in Airway Volumes Detectable by Functional Respiratory Imaging in Patients With Moderate-severe Asthma (VESTIGE)

Asthma

Portugal, Ukraine, Spain, Taiwan, Sweden, United States, Bulgaria, Denmark, France, Italy, Romania, Saudi Arabia, United Kingdom
Regeneron Pharmaceuticals
Sanofi

Active, not recruiting

Study to Investigate the Efficacy and Safety of Dupilumab in Pediatric Patients With Active Eosinophilic Esophagitis (EoE) (EoE KIDS)

Eosinophilic Esophagitis (EoE)

United States, Canada
Regeneron Pharmaceuticals
Sanofi

Active, not recruiting

Study to Assess the Long-term Safety of Dupilumab Administered in Participants ≥6 Months to <18 Years of Age With Atopic Dermatitis (AD)

Atopic Dermatitis

United States, Canada, Czechia, Germany, Hungary, Poland, United Kingdom
Sanofi
Regeneron Pharmaceuticals

Completed

Efficacy and Safety Study of Dupilumab in Patients With Persistent Asthma

Asthma

China, India
Sanofi
Regeneron Pharmaceuticals

Completed

Study of Dupilumab for the Treatment of Patients With Prurigo Nodularis, Inadequately Controlled on Topical Prescription Therapies or When Those Therapies Are Not Advisable (PRIME2)

Neurodermatitis

United States, Canada, Chile, France, Hungary, Italy, Korea, Republic of, Portugal, Spain, Taiwan, United Kingdom
Sanofi
Regeneron Pharmaceuticals

Completed

Comparative Efficacy of Cemiplimab to Historical Standard of Care in France (TOSCA)

Cancer/Squamous Cell Carcinoma of Skin

France
Sanofi
Regeneron Pharmaceuticals

Completed

Study of Dupilumab for the Treatment of Patients With Prurigo Nodularis, Inadequately Controlled on Topical Prescription Therapies or When Those Therapies Are Not Advisable (LIBERTY-PN PRIME)

Neurodermatitis

France, United States, Argentina, China, Japan, Korea, Republic of, Mexico, Russian Federation
Regeneron Pharmaceuticals
Sanofi

Terminated

REGN2810 (Anti-PD-1 Antibody), Platinum-based Doublet Chemotherapy, and Ipilimumab (Anti-CTLA-4 Antibody) Versus Pembrolizumab Monotherapy in Patients With Lung Cancer

Non-small Cell Lung Cancer

United States, Italy, Lithuania
Sanofi
Regeneron Pharmaceuticals

Completed

Evaluation of SAR440340 and as Combination Therapy With Dupilumab in Moderate-to-Severe Asthma Participants

Asthma

Ukraine, United States, Argentina, Chile, Mexico, Poland, Russian Federation, Turkey
Sanofi
Regeneron Pharmaceuticals

Completed

Effect of Sarilumab on Patient-reported Outcomes in Patients With Active Rheumatoid Arthritis (SariPRO)

Rheumatoid Arthritis

France
Sanofi
Regeneron Pharmaceuticals

Terminated

Evaluation of Efficacy and Safety of Sarilumab in Patients With GCA

Giant Cell Arteritis

Argentina, Estonia, France, United States, Australia, Belgium, Canada, Croatia, Denmark, Germany, Hungary, Israel, Italy, Netherlands, Portugal, Russian Federation, Slovenia, Spain, Sweden, Switzerland, United Kingdom
Sanofi
Regeneron Pharmaceuticals

Completed

An Efficacy and Safety Study of Alirocumab in Children and Adolescents With Homozygous Familial Hypercholesterolemia

Hypercholesterolemia

Slovenia, Taiwan, Russian Federation, Canada, Netherlands, Brazil, Denmark, Mexico, Spain, Turkey
Regeneron Pharmaceuticals
Sanofi

Terminated

A Study of Aflibercept Administered in Combination With Pemetrexed and Cisplatin in Participants With Advanced Carcinoma

Non-small Cell Lung Cancer | Advanced Carcinoma

United States, Canada
Regeneron Pharmaceuticals
Sanofi

Completed

Open-Label Extension of Study R727-CL-1003 (NCT01266876) to Evaluate the Long-Term Safety and Efficacy of Alirocumab (REGN727) in Participants With Heterozygous Familial Hypercholesterolemia (HeFH)

Hypercholesterolemia | Heterozygous Familial Hypercholesterolemia

United States, Canada
Regeneron Pharmaceuticals
Sanofi

Completed

Study of Dupilumab (REGN668/SAR231893) Monotherapy Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis (SOLO 2)

Dermatitis, Atopic

United States, France, Poland, United Kingdom, Germany, Hong Kong, Canada, Korea, Republic of, Italy, Lithuania, Sweden
Regeneron Pharmaceuticals
Sanofi

Completed

Study of Alirocumab (REGN727/SAR236553) in Patients With Heterozygous Familial Hypercholesterolemia (HeFH) Undergoing Low-density Lipoprotein (LDL) Apheresis Therapy (ODYSSEY ESCAPE)

Heterozygous Familial Hypercholesterolemia

United States, Germany
Regeneron Pharmaceuticals
Sanofi

Completed

Study of Alirocumab (REGN727/SAR236553) added-on to Rosuvastatin Versus Other Lipid Modifying Treatments (LMT) (ODYSSEY OPTIONS II)

Hypercholesterolemia

United States, France, Italy, Germany, Spain, Canada, United Kingdom, Australia, Mexico
Regeneron Pharmaceuticals
Sanofi

Completed

Study to Determine the Safety and Effectiveness of Dupilumab for Treatment of Atopic Dermatitis (AD)

Atopic Dermatitis (AD)

United States, Canada
Sanofi
Regeneron Pharmaceuticals

Completed

Controlled Clinical Study of Dupilumab in Patients With Nasal Polyps (SINUS-52)

Chronic Rhinosinusitis Phenotype With Nasal Polyps (CRSwNP)

Belgium, Mexico, Turkey, Israel, Spain, Sweden, Argentina, Canada, Japan, United States, Australia, Chile, Portugal, Russian Federation
Sanofi
Regeneron Pharmaceuticals

Completed

Evaluation of Dupilumab in Patients With Persistent Asthma (Liberty Asthma Quest)

Asthma

Spain, Canada, United States, Korea, Republic of, Mexico, Brazil, Germany, Taiwan, Argentina, Australia, Colombia, France, Hungary, Japan, Poland, Russian Federation, South Africa, Turkey, Ukraine, United Kingdom, Italy, Chile
Regeneron Pharmaceuticals
Sanofi

Completed

Study of Dupilumab in Adult Patients With Extrinsic Moderate-to-Severe Atopic Dermatitis

Atopic Dermatitis

Poland, Germany, France, Hungary, Czechia
Regeneron Pharmaceuticals
Sanofi

Completed

Study of Dupilumab Auto-injector Device When Used by Patients With Atopic Dermatitis

Eczema, Atopic | Atopic Disorders

United States
Sanofi
Regeneron Pharmaceuticals

Completed

Efficacy and Safety of Alirocumab Versus Usual Care on Top of Maximally Tolerated Statin Therapy in Patients With Type 2 Diabetes and Mixed Dyslipidemia (ODYSSEY DM-Dyslipidemia)

Dyslipidemia

United States, Australia, Brazil, Finland, Germany, Israel, Italy, Kuwait, Lebanon, Norway, Sweden, Switzerland, Turkey, United Arab Emirates, United Kingdom
Sanofi
Regeneron Pharmaceuticals

Completed

Safety and Quality of Life Study of Aflibercept in Patients With Metastatic Colorectal Cancer Previously Treated With an Oxaliplatin-Based Regimen

Colorectal Cancer Metastatic

Italy, Spain, United Kingdom, Czechia, Russian Federation, Norway, Thailand, Chile, Israel, Brazil, United States, Belgium, Canada, Denmark, Finland, Germany, Ireland, Lebanon, Mexico, Netherlands, Puerto Rico, Sweden, Turkey
Sanofi
Regeneron Pharmaceuticals

Completed

A Study Assessing the Efficacy and Safety of Sarilumab Added to MTX in Japanese Patients With Moderately to Severely Active Rheumatoid Arthritis (SARIL-RA-KAKEHASI)

Rheumatoid Arthritis

Japan
Regeneron Pharmaceuticals
Sanofi

Completed

Study of Dupilumab Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis

Atopic Dermatitis

United States, Germany, Poland, Japan, Canada, Hungary, Czechia
Sanofi
Regeneron Pharmaceuticals

Completed

To Evaluate The Effect Of SAR153191 (REGN88) Added To Other RA Drugs In Patients With RA Who Are Not Responding To Or Intolerant Of Anti-TNF Therapy (SARIL-RA-TARGET)

Rheumatoid Arthritis

Hungary, Portugal, Austria, United States, Argentina, Australia, Brazil, Canada, Czechia, Germany, Greece, Guatemala, Israel, Italy, Korea, Republic of, Lithuania, Mexico, New Zealand, Peru, Poland, Romania, Russian Federation, Spain, Taiwa... and more
Sanofi
Regeneron Pharmaceuticals

Completed

Dose Ranging Study to Evaluate the Efficacy and Safety of SAR153191 (REGN88) in Patients With Ankylosing Spondylitis (ALIGN)

Ankylosing Spondylitis

Germany, Hungary, Belgium, Czechia, Austria, Canada, Lithuania, Poland, Spain, Turkey, France, Netherlands, United States, Australia
Sanofi
Regeneron Pharmaceuticals

Completed

Evaluation of Sarilumab (SAR153191/REGN88) on Top of Methotrexate in Rheumatoid Arthritis Patients (RA-MOBILITY)

Rheumatoid Arthritis

Germany, Hungary, Belgium, United States, Argentina, Australia, Austria, Belarus, Brazil, Canada, Chile, Czechia, Estonia, Finland, Greece, Korea, Republic of, Lithuania, Malaysia, Mexico, New Zealand, Philippines, Poland, Romania, Russian... and more
Sanofi
Regeneron Pharmaceuticals

Completed

Evaluation of Alirocumab in Addition to Lipid-Modifying Therapy in Patients With High Cardiovascular Risk and Hypercholesterolemia in South Korea and Taiwan

Hypercholesterolemia

Korea, Republic of, Taiwan
Sanofi
Regeneron Pharmaceuticals

Completed

An Evaluation of Dupilumab in Patients With Nasal Polyposis And Chronic Symptoms Of Sinusitis

Nasal Polyps

Spain, Belgium, United States, Sweden
Sanofi
Regeneron Pharmaceuticals

Terminated

Extension Study for Long Term Evaluation of SAR153191 (REGN88) in Patients With Ankylosing Spondylitis (SUSTAIN)

Ankylosing Spondylitis

United States, France, Canada, Poland, Netherlands, Spain, Belgium, Hungary, Lithuania, Austria, Czechia, Australia
Regeneron Pharmaceuticals
Sanofi

Completed

Study to Evaluate the Efficacy and Safety of an Every Four Weeks Treatment Regimen of Alirocumab (REGN727/ SAR236553) in Patients With Primary Hypercholesterolemia (ODYSSEY CHOICE 1)

Hypercholesterolemia

United States, Bulgaria, Canada, Norway, Israel, Slovakia, United Kingdom, Hungary
Sanofi
Regeneron Pharmaceuticals

Completed

Efficacy and Safety Evaluation of Alirocumab in Patients With Heterozygous Familial Hypercholesterolemia or High Cardiovascular Risk Patients With Hypercholesterolemia on Lipid Modifying Therapy (ODYSSEY JAPAN)

Hypercholesterolemia

Japan
Sanofi
Regeneron Pharmaceuticals

Completed

Ascending Dose Study of the Safety and Tolerability of Alirocumab (SAR236553/REGN727) in Japanese Healthy Volunteers

Hypercholesterolemia

Japan
Sanofi
Regeneron Pharmaceuticals

Completed

Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Ezetimibe on Top of Statin in High Cardiovascular Risk Patients With Hypercholesterolemia (ODYSSEY COMBO II)

Hypercholesterolemia

United States, Canada, Denmark, France, Hungary, Israel, Korea, Republic of, Russian Federation, South Africa, Ukraine

Clinical Trials Sponsored by Sanofi-Regeneron

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Uzbekistan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations